RT Journal Article
T1 Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.
A1 Quesada-Gomez, Jose Manuel
A1 Entrenas-Castillo, Marta
A1 Bouillon, Roger
K1 1α, 25(OH)2D or 1α, 25-dihydroxyvitamin D or calcitriol
K1 Acute respiratory distress syndrome (ARDS)
K1 Calcifediol or 25-hydroxyvitamin D3
K1 Corona virus
K1 Cytokine storm
K1 Hypercoagulability
K1 Lung diseases
K1 Renin-angiotensin system
K1 SARS-CoV-2
K1 Vitamin D, vitamin D3 or cholecalciferol
AB Coronavirus infection is a serious health problem awaiting an effective vaccine and/or antiviral treatment. The major complication of coronavirus disease 2019 (COVID-19), the Acute Respiratory Distress syndrome (ARDS), is due to a variety of mechanisms including cytokine storm, dysregulation of the renin-angiotensin system, neutrophil activation and increased (micro)coagulation. Based on many preclinical studies and observational data in humans, ARDS may be aggravated by vitamin D deficiency and tapered down by activation of the vitamin D receptor. Several randomized clinical trials using either oral vitamin D or oral Calcifediol (25OHD) are ongoing. Based on a pilot study, oral calcifediol may be the most promising approach. These studies are expected to provide guidelines within a few months.
PB Elsevier
YR 2020
FD 2020-06-07
LK http://hdl.handle.net/10668/15734
UL http://hdl.handle.net/10668/15734
LA en
NO Quesada-Gomez JM, Entrenas-Castillo M, Bouillon R. Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166. J Steroid Biochem Mol Biol. 2020 Sep;202:105719
NO This work was supported by grants COVID-011-2020 “Programa de Investigación clínica en COVID-19 de Andalucía”. Consejería de Salud yFamilia. Fundación Progreso y Salud y Fundación para la InvestigaciónBiomédica de Córdoba (FIBICO). Andalucía. Spain.
DS RISalud
RD Apr 6, 2025